Lung cancer is the third most common cancer in the UK, with around 48,500 people diagnosed each year. There are two main types of lung cancer – small cell lung cancer and non small cell lung cancer – depending on how the cells look under the microscope.
The main symptoms are a cough, shortness of breath and weight loss.
The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer.
New data suggest that targeted therapy seems to be having an impact on the treatment of lung cancer.
The National Lung Matrix Trial – a £25 million collaboration with pharmaceutical companies and the NHS – has been exploring how patients with non small cell lung cancer respond to more tailored, targeted treatments.
Cancer Research UK scientists have developed a new way to analyse blood for evidence of cancer that could be up to ten times more sensitive than previous methods.
A new immunotherapy treatment has been recommended by the National Institute for Health and Care Excellence (NICE) for some adults with small cell lung cancer.
Scientists working on the TRACERx project have mapped how the immune systems responds to lung tumours over time
The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland
New research reveals how some cancer cells double their genome to help them survive. Find out more about cancer’s ‘spare tyre’.
Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua).